跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MAVIRET 50 MG/20 MG GRANULOS RECUBIERTOS EN SOBRE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
MAVIRET 50 MG/20 MG GRANULOS RECUBIERTOS EN SOBRE
Approved
STANDARD
MAVIRET 50 MG/20 MG GRANULOS RECUBIERTOS EN SOBRE
Abbvie Deutschland Gmbh & Co. Kg
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Dec 23, 2021
Approval ID
fff5f39250117de7
Company
Abbvie Deutschland Gmbh & Co. Kg
Type
Standard
Approval Details
Approval Id
fff5f39250117de7
Drug Cima Aemps Name
MAVIRET 50 MG/20 MG GRANULOS RECUBIERTOS EN SOBRE
Register Number
1171213002
Holder Company Name
Abbvie Deutschland Gmbh & Co. Kg
Marketing Company Name
Abbvie Spain, S.L.U.
Holder Company Detail Path
/organization/abbvie-deutschland-gmbh-and-co-kg
Authorization Date
2021-12-23
Dosage Form
GRANULOS RECUBIERTOS EN SOBRES
Dose
50 mg/20 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Abbvie Deutschland Gmbh & Co. Kg
Company Detail Path
/organization/abbvie-deutschland-gmbh-and-co-kg
Company Information
Pharmaceutical Company Name
AbbVie Deutschland GmbH & Co. KG
Country Name
Germany
City Name
ludwigshafen am rhein,rheinland-pfalz,country_de
Address
Knollstr. 50
Website
http://www.abbvie.de
Active Ingredients
GLECAPREVIR
50 mg
PIBRENTASVIR
20 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Dec 23, 2021
Approval ID
fff5f39250117de7
Type
Standard
Back to CIMA-AEMPS Approvals
